These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 2959426

  • 1. Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.
    Winer N, Thys-Jacobs S, Kumar R, Davidson WD, Grayson M, Harris C, Walker D, Itskovitz H, Gonasun L.
    Clin Pharmacol Ther; 1987 Oct; 42(4):442-8. PubMed ID: 2959426
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.
    Nelson EB, Pool JL, Taylor AA.
    Clin Pharmacol Ther; 1986 Dec; 40(6):694-7. PubMed ID: 2946507
    [Abstract] [Full Text] [Related]

  • 3. Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension.
    Winer N, Kirkendall WM, Canosa FL, Lewin AJ, McMahon FG, Carr AA, Cohen M.
    J Clin Pharmacol; 1990 Nov; 30(11):1006-11. PubMed ID: 2147029
    [Abstract] [Full Text] [Related]

  • 4. Treatment of essential hypertension with PN 200-110 (isradipine).
    Hamilton BP.
    Am J Cardiol; 1987 Jan 30; 59(3):141B-145B. PubMed ID: 2949585
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
    Kirch W, Burger KJ, Weidinger G, Welzel D.
    J Cardiovasc Pharmacol; 1990 Jan 30; 15 Suppl 1():S55-9. PubMed ID: 1695304
    [Abstract] [Full Text] [Related]

  • 6. Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.
    Staessen J, Lijnen P, Fagard R, Hespel P, Tan WP, Devos P, Amery A.
    J Cardiovasc Pharmacol; 1989 Feb 30; 13(2):271-6. PubMed ID: 2468957
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of isradipine in hypertension.
    Shepherd AM, Carr AA, Davidov M, Hamilton J, Schnaper H, Velasquez M, Brockway B, Prisant LM, Hamilton B, Gonasun L.
    J Cardiovasc Pharmacol; 1989 Apr 30; 13(4):580-5. PubMed ID: 2470995
    [Abstract] [Full Text] [Related]

  • 8. Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study.
    Mohanty PK, Gonasun LM, Goodman RP, Kirkendal WM, Kontos HA, Samuel P, Wright JT.
    Am J Hypertens; 1988 Jul 30; 1(3 Pt 3):241S-244S. PubMed ID: 2970853
    [Abstract] [Full Text] [Related]

  • 9. An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients.
    McMahon FG, Vargas R, Ryan JR, Miller H, Faraday S.
    J Clin Pharmacol; 1988 Jul 30; 28(7):664-6. PubMed ID: 2975291
    [Abstract] [Full Text] [Related]

  • 10. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Welzel D, Burger KJ, Weidinger G.
    J Cardiovasc Pharmacol; 1990 Jul 30; 15 Suppl 1():S70-4. PubMed ID: 1695308
    [Abstract] [Full Text] [Related]

  • 11. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine.
    Welzel D, Burger KJ.
    Drugs; 1990 Jul 30; 40 Suppl 2():60-4. PubMed ID: 2150644
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
    Am J Med; 1989 Apr 17; 86(4A):110-4. PubMed ID: 2523644
    [Abstract] [Full Text] [Related]

  • 13. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension.
    Persson B, Wysocki M, Andersson OK.
    J Cardiovasc Pharmacol; 1989 Jul 17; 14(1):22-4. PubMed ID: 2475710
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients.
    Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF.
    J Cardiovasc Pharmacol; 1992 Jul 17; 19 Suppl 3():S53-7. PubMed ID: 1376836
    [Abstract] [Full Text] [Related]

  • 15. Antihypertensive effect of a new dihydropyridine calcium antagonist, PN 200-110 (isradipine), combined with pindolol.
    Hansson L, Dahlof B.
    Am J Cardiol; 1987 Jan 30; 59(3):137B-140B. PubMed ID: 2949584
    [Abstract] [Full Text] [Related]

  • 16. Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
    Cantor A, Cristal N.
    J Cardiovasc Pharmacol; 1990 Jan 30; 15 Suppl 1():S76-8. PubMed ID: 1695309
    [Abstract] [Full Text] [Related]

  • 17. A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension.
    Sundstedt CD, Rüegg PC, Keller A, Waite R.
    Am J Med; 1989 Apr 17; 86(4A):98-102. PubMed ID: 2523665
    [Abstract] [Full Text] [Related]

  • 18. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group.
    Drugs; 1987 Apr 17; 34 Suppl 3():139-48. PubMed ID: 2894973
    [Abstract] [Full Text] [Related]

  • 19. Additive effect of isradipine in combination with captopril in hypertensive patients.
    Eggertsen R, Svensson A, Dahlöf B, Hansson L.
    Am J Med; 1989 Apr 17; 86(4A):124-6. PubMed ID: 2523647
    [Abstract] [Full Text] [Related]

  • 20. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation.
    Prisant LM, Carr AA, Nelson EB, Winer N, Velasquez MT, Gonasun LM.
    Arch Intern Med; 1989 Nov 17; 149(11):2453-7. PubMed ID: 2530945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.